This document discusses menopause and management options. It begins by defining menopause as the permanent cessation of menstruation resulting from loss of ovarian activity, typically between ages 45-55. It then outlines some of the main consequences of menopause like vasomotor symptoms, sexual dysfunction, osteoporosis, and cardiovascular risks. The document discusses treatment options like lifestyle changes, hormone replacement therapy, and alternative therapies. It provides details on hormone replacement regimens and duration of treatment for various symptoms and conditions.
Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovaries stop producing the hormones estrogen and progesterone. A woman has reached menopause when she has not had a period for one year.
Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovaries stop producing the hormones estrogen and progesterone. A woman has reached menopause when she has not had a period for one year.
Menopause: Symptoms, Concerns, and Management StrategiesSummit Health
Presentation about menopause, including information about common symptoms such as hot flashes, sleeplessness, and weight gain as well as other physiologic changes such as bone loss and cardiovascular risks. Dr. Gibbons and Dr. Cummings will offer recommendations on treatment and management options that can help you navigate this important life transition.
Allison Taylor, MD, with the Center for Women's Health in Wichita, KS, presented about perimenopause and hormone therapy during a Women's Connection July 9, 2013, at Corporate Caterers. The event is sponsored by Via Christi Health.
in this slide physiological, psychological and social aspects of menopause, Hormonal replacement therapy, surgical menopause , guidance and counselling / role of midwifery nurse practitioner in menopause.
Menstrual cycle irregularities can have many different causes. For some women, use of birth control pills can help regulate menstrual cycles. However, some menstrual irregularities can't be prevented. Regular pelvic exams can help ensure that problems affecting your reproductive organs are diagnosed as soon as possible.
Menopause: Symptoms, Concerns, and Management StrategiesSummit Health
Presentation about menopause, including information about common symptoms such as hot flashes, sleeplessness, and weight gain as well as other physiologic changes such as bone loss and cardiovascular risks. Dr. Gibbons and Dr. Cummings will offer recommendations on treatment and management options that can help you navigate this important life transition.
Allison Taylor, MD, with the Center for Women's Health in Wichita, KS, presented about perimenopause and hormone therapy during a Women's Connection July 9, 2013, at Corporate Caterers. The event is sponsored by Via Christi Health.
in this slide physiological, psychological and social aspects of menopause, Hormonal replacement therapy, surgical menopause , guidance and counselling / role of midwifery nurse practitioner in menopause.
Menstrual cycle irregularities can have many different causes. For some women, use of birth control pills can help regulate menstrual cycles. However, some menstrual irregularities can't be prevented. Regular pelvic exams can help ensure that problems affecting your reproductive organs are diagnosed as soon as possible.
causes ,aetiology of pain during menstrual cycle and treatment.
causes and treatment for anxiety before menstrual cycle
non pharmacological treatment of anxiety before periods
different gynaecological problems
pscycological aspects of the dysmenorrhoea
pharmacological management of dysmenorrhoea
@women health , #menopause ,#DEFINITION OF MENOPAUSE
● @STAGES OF MENOPAUSE
● #MENOPAUSAL SYMPTOMS
● @TREATMENT OPTIONS
12 months of amenorrhea
without any other obvious
pathological cause or
physiological cause.
Why menopause
occurs in old women?
Polycystic ovary syndrome history, modern and unani approach ppt.pptxFaizaFurqan1
Poly cystic ovarian syndrome pptx.
Including history of pcos
Relation to diet
decrease in metabolism
Central obesity
recent diagnostic criterias
Unani concept
single and compound drugs
modern medicine treatment and unani medicine treatment
ACOG guidelines and description given by ancient scholars
Action of drugs used by gynec in their OPDS
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
2. Life After MenopauseLife After Menopause
Age at menopause : 51.7 (average)
1900 : life expectancy at 40 years old
1950 : life expectancy at 65 years old
2000 : life expectancy at 83 years old
(Malaysian women - 75.4 years)
3. “Women now live
a third of their lives
after menopause”
8th International Congress on Menopause, Sydney 1996
4.
5. MenopauseMenopause
MenopauseMenopause is the permanentis the permanent
cessation of menstruation thatcessation of menstruation that
results from loss of ovarian follicularresults from loss of ovarian follicular
activity.activity.
Menopausal age :Menopausal age : 45 – 55 years45 – 55 years
Mean age ( M )Mean age ( M ) :: 50.7 years50.7 years
Premature menopausePremature menopause < 45< 45
yearsyears
Late menopauseLate menopause > 55 years> 55 years
6. is the cessation of menstruationis the cessation of menstruation
that follows surgical removal ofthat follows surgical removal of
both ovaries orboth ovaries or iatrogenic ablationiatrogenic ablation
of ovarian functionof ovarian function byby
chemotherapy, radiotherapy orchemotherapy, radiotherapy or
treatment with GnRH analogues.treatment with GnRH analogues.
Induced /surgical menopauseInduced /surgical menopause
7. PerimenopausePerimenopause
Is the period beginnning with the first
clinical, biological and endocrinological
features of the approaching
menopause such as vasomotor
symptoms and menstrual irregularity
Can be 1 or 2 years and for some as
long as 7 to 10 year
8. DiagnosisDiagnosis
For those 50 years and above :For those 50 years and above :
12 consecutive month of12 consecutive month of
amenorrhoea is diagnostic.amenorrhoea is diagnostic.
For those below 50 years :For those below 50 years :
** FSHFSH > 30 IU/l> 30 IU/l
9. Consequences of menapauseConsequences of menapause
Vasomotor
symptoms
Psychological
symptoms
Sexual dysfunction
Osteoporosis
Cardiovascular
Disease
Urogenital Atrophy
10. Vasomotor SymptomsVasomotor Symptoms
Hot flushes and night sweats are
experienced by as many as 85% of
women around the menopause.
Most would experience these symptoms
for < 5 years, however about 25%
would experience it for more than 5
years.
11. Sexual DysfunctionSexual Dysfunction
The underlying problem for female sexual
dysfunction are usually multifactorial.
Oestrogen deficiency can lead vaginal dryness
and dyspareunia,
Non hormonal factors such as conflict between
partners, insomnia, inadequate stimulation,
life stresses can also lead to sexual
dysfunction.
12. Depressed mood, anxiety, irritability,
mood swings, lethargy and lack of
energy have been associated with the
menopause.
General population studies suggest that
most women do not experience major
mood changes during the menopause.
Psychological SymptomsPsychological Symptoms
14. OsteoporosisOsteoporosis
Affects 1:3 women.
Risk factors include family history of fracture,
low BMI, early menopause, cigarette smoking,
alcohol abuse, sedentary lifestyle,
corticosteroids, hyperthyroidism.
Common sites for osteoporotic fracture are
lower end of radius (wrist/Colles’ fracture),
proximal femur (hip) and vertebrae.
15. Cardiovascular DiseaseCardiovascular Disease
common cause of death in women after the
age of 60 years.
Risk factors for myocardial infarction are
abnormal FLP, smoking, depression and
stress.
Incidence of stroke increases with age.
Risk factors are hypertension, smoking,
diabetes, hyperlipidaemia, obesity.
16. Urogenital AtrophyUrogenital Atrophy
Oestrogen and progestrone receptors are
present in the vagina, urethra, bladder and
pelvic floor musculature.
Oestrogen deficiency after menopause cause
atrophic changes in the urogenital tract and is
associated with urinary symptoms which may
co-exist with symptoms of vaginal atrophy.
17. Treatment OptionTreatment Option
Making lifestyle changes - healthy
diet, exercise and stress reduction.
Hormone replacement therapy.
Complementary and alternative
therapies.
21. OestrogensOestrogens
Natural : oestradiol, oestrone and
oestriol which are chemically
synthesised from soya beans or yams;
conjugated equine oestrogen (CEE)
consisting primarily of estrone sulphate
and equilin sulphate,obtained from
urine of pregnant horses,
Synthetic : ethinyl oestradiol and
mestranol (less suitable for HRT)
22. ProgestogensProgestogens
High androgenic potency
marked adverse effects on lipoproteins!
negates beneficial effects of estrogen
eg. 19-nor progestogens, norgestrel,
norethisterone
Moderate androgenic potency
some effects on plasma lipids
eg. Medroxyprogesterone acetate (MPA)
23. No androgenic potency
no effect on blood lipids
Eg dydrogesterone (Duphaston)
Eg - Femaston
24. Routes of AdministrationRoutes of Administration
Oral
-most widely used
-well tolerated
-highly effective
-rapid onset
-‘first-pass’ effect
(beneficial changes in
HDL:LDL)
Transdermal
-patches or gels
-messy, time consuming
-redness/itchiness
-need of oral progestogen:
low compliance
Intravaginal
-vaginal rings, pessaries,
cream
-no effects on vasomotor
symptoms, osteoporosis or
CVD
-creams or tablets:messy
-need oral progestogen: poor
compliance
Subcutaneous
-surgically inserted pellets
-hormone release varies
-treatment can’t be
reversed
-estrogen effects persist
25. Prescribing RegimensPrescribing Regimens
Estrogen therapy may be
cyclical :administered for first 21 days of
the cycle)
continuous :administered throughout the
cycle)
Progestogens therapy may be
sequentially :added for last 10 - 14 days of
the cycle (induces a withdraw bleed)
continuously (to eliminate withdrawal bleed)
28. % change from baseline after 24 months (n=26, n=28, n=26)
Hänggi W et al. Endocrinology 1998;48:691-699.
Effect of HRT on Body
Weight and Fat Distribution
-2
0
2
4
6
Total Body
Fat Mass
Trunk
Fat mass
Total Body
Weight
Controls
Tibolone
femoston 2/10
*
*p<0.05 vs. baseline
* *
%changefrombaseline
29. Sequential TherapySequential Therapy
Mimics the menstrual cycle.
Regular, monthly periods.
Periods often lighter.
Appropriate for perimenopausal women
with irregular bleed.
30. Continuous Combined RegimeContinuous Combined Regime
A continuous-combined regime is to
eliminate wihdrawal bleeding.
Use should be avoided within the first
12 months after the last menstrual
bleed.
Spottings may occur during the first 3 -
4 months in most women.
Appropriate for postmenopausal women
who do not wish for any regular
withdrawal bleed.
31. Duration of SystemicDuration of Systemic
TreatmentTreatment
Vasomotor symptoms - up to 5 years
and then evaluate as some women do
experience symptoms for more than 5
years.
Prevention or treatment of
osteoporosis - needs to be continued
for life as BMD falls when treatment is
stopped. However other option should
be discussed as long term HRT is
associated with other risk.
32. Premature menopause - usually
advised to continue until the natural age
of menopause ~ 51 years. There after
need to reevaluate what is the endpoint
of treatment.
33. Treatment of LocalTreatment of Local
SymptomsSymptoms
Treatment is usually long term if not life long
as symptom return on cessation of treatment.
Synthetic oestrogens or CEE should be avoided
as they are well absorbed from the vagina.
The options available are low dose natural
oestrogen e.g vaginal oestriol by cream or
pessary or oestradiol by tablet or ring.
With the recommended dose regimen,
progestogen need not be added for endometrial
protection.
34. - effective in treating hot flushes and
improvement is usually seen within 4 weeks
with maximum effect achieved by 3 months.
- treatment should be continued for at least 1
year.
Vasomotor symptomsVasomotor symptoms
35. Percentage of menopausal symptoms in 186 women
during a 52 week period of femoston®
2/10 treatment
Baseline
6 weeks
52 weeks
0
10
20
30
40
50
60
70
80
Hot
flushes
Night
sweats
Sweating
attacks
Vaginal
dryness
Painful
intercourse
Percentageofwomen
Amy JJ. Eur Menop J 1995;2 (Suppl.):16-22
Relief of Menopause Symptoms
with femoston®
2/10
36. Urogenital symptoms and sexualityUrogenital symptoms and sexuality
- vaginal dryness, superficial
dyspareunia, urinary frequency and
urgency respond well to oestrogens
- urinary incontinence, however, is
not improved
37. - reduces the risk of spine, hip and other
osteoporotic fracture.
- need lifelong treatment to be effective in
preventing fracture.
- not recommended as a first-line treatment as
risks outweigh benefits.
- standard dose for bone protection are CEE
0.625mg, oestradiol 1-2mg and transdermal
25-50µg.
OsteoporosisOsteoporosis
38. Bone Mineral Density % Change
Stevenson JC et al. Maturitas 2001;38:197-203.
Significant increase in BMD of the lumbar vertebrae and hips
1 mg estradiol plus 5, 10 or 20 mg continuous dydrogesterone,
N=177, 1 year treatment duration
* p<0.01 vs. baseline
0.0%
1.0%
2.0%
3.0%
4.0%
L2-4 Vertebrae Femoral
Neck
Ward's
Triangle
Trochanter
3.6%*
1.16%*
1.62%*
2.83%*
%increasefrombaseline
39. Prevention and Treatment ofPrevention and Treatment of
OsteoporosisOsteoporosis
Biphosphonates
- shown to reduce both vertebral and non-
vertebral fractures
- principal side-effect : irritation of upper GIT so
given weekly/monthly to reduce this. Eg -
alandroanate
SERMs (Raloxifene)
- shown to reduce vertebral fracture.
- does not treat vasomotor symptoms, cause
transient side effects such as hot flushes and
leg cramps.
- Has an equal propensity with HRT to cause
VTE
40. Prevention and TreatmentPrevention and Treatment
of Osteoporosisof Osteoporosis
Calcitriol
- active metabolite of vitamin D and facilitates
the intestinal absorption of calcium.
Calcium
- in postmenopausal women not on HRT 1.5
gram/day and in those on HRT 1.0 gram/day
of elemental calcium is needed to preserve
bone health.
Vitamin D
- oral supplementation of 700-800IU/day seem
to reduce risk of vertebral and non-vertebral
fractures in ambulatory or institutionalized
elderly people.
42. HRT AND Breast cancerHRT AND Breast cancer
- risk of breast cancer is dependent on
the regimen prescribed, greatest with
combined oestrogen-progestrogen
replacement.
- Risk of breast cancer minimal after 5
years of usage
- The WHI found : risk in the oestrogen-
alone group was 23% lower than in the
placebo group.
43. Nurses' Health Study (January 2006Nurses' Health Study (January 2006))
Data suggest that timing of hormone
initiation in relation to age of onset
of menopause might influence
coronary risk; women beginning
HT/ET near onset of menopause had
a significantly reduced risk (30%
less) of CHD;
no significant correlation between
HT/ET and CHD risk was observed
among women who initiated therapy
10 years or more after menopause.
Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart
disease: the role of time since menopause and age at hormone initiation.
44. Effects of unopposed estrogen and risk of invasiveEffects of unopposed estrogen and risk of invasive
breast cancer (Nurses' Health Study, May 2006)breast cancer (Nurses' Health Study, May 2006)
Data indicate that use of estrogen
alone did not increase the risk of
invasive breast cancer until 20 years
of use and beyond, and risk was
increased at 15 years for estrogen
receptor and progesterone receptor-
positive cancers.
Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and
the risk of invasive breast cancer. Arch Intern Med. 2006;166:1027-1032.
45. Breast DisorderBreast Disorder
Benign breast disease - no
convincing evidence to show that the
risk of breast cancer is increased in
patients with benign breast disease
Previous breast cancer - studies on
systemic HRT showed contradictory
results with some showing adverse
outcome and some showed no further
increase risk. However, low dose
vaginal oestrogen are not
contraindicated for vaginal symptoms.
46. HRT AND Endometrial cancerHRT AND Endometrial cancer
- unopposed oestrogen therapy increased
the risk of endometrial cancer and risk
is still increased for 5 years or more
after discontinuation of therapy.
- addition of progestogen reduces this
risk but not completely with sequential
progestogens especially if used for more
than 5 years.
- no increase risk is found with combined
continuous regimen.
47. HRT andHRT and VenousVenous
thromboembolic diseasethromboembolic disease
- highest risk occurs in the first year of
use.
- however, absolute risk is small as VTE
occurs in 1.7 per 1000 in women older
than 50 years who are not taking HRT
and mortality is low (1-2%).
- limited data suggest that transdermal
HRT is associated with a lower risk than
the oral route.
48. HRT and CANCERHRT and CANCER
Cervical and ovarian cancer -
not contraindicated except for
endometrioid ovarian cancer where
some doubt exist and progestogen
addition is recommended.
Endometrial cancer - need to be
given with progestogen.
49. Cardiovascular DiseaseCardiovascular Disease
Hypertension - no evidence shows that oestradiol-
based HRT increases blood pressure or has an adverse
effect in women with hypertension. Rarely CEE may
cause severe hypertension which returns to normal
upon stopping treatment.
Hyperlipidaemia - depends on type of HRT used.
Venous thromboembolism - relative contraindication.
If still need to give as benefits outweighed risks then
the transdermal route might be safer (limited evidence)
HRT and surgery - to stop 4 weeks prior to elective
surgery or to continue HRT with thromboprophylaxis.
50. Endocrine DiseaseEndocrine Disease
Diabetes Mellitus - HRT seems to
improve the glycaemic control with
varying results depending on the type
and route of administion.
Thyroid disease - dose of thyroxine
may need to be increased as oestrogen
can can increase the concentration of
thyroxine-binding globulin.
51. Non-oestrogen Based TreatmentNon-oestrogen Based Treatment
Menopausal symptoms
- progestogens such as NET 5mg/day or
megestrol acetate 40mg/day
- Clonidine - 50-75mg bd, of limited
value and effectiveness
- SSRI, gabapentin
Vaginal atrophy
- lubricants, moisturisers
52. What are other options?What are other options?
Exercise – yoga, Taichi, meditations
Healthy food – increase fruits and
vegetable intake
Alternative – black cohosh, red
clovers, etc
54. Case Study 1Case Study 1
45 year old woman, para 3,
complains of:
irregular bleeding (not heavy)
vasomotor symptoms (hot
flushes, night sweats)
What would you advise her ?What would you advise her ?
55. Case Study 1Case Study 1
1.1. Health ScreenHealth Screen
• Detailed history of general health status including family history
• Physical examination: BP, Anemia, Thyroid, CVS, Lung, Breasts,
Pelvic examination including Pap Smear.
• Blood Examination: Hb, Lipid profiles, FBS, Others if indicated.
• Other investigations: Mammography, BMD (Dexa)
2. Treatment …
If all tests are normal the choices are:
• Combined Cyclical HRT (regular-bleed)
56. Case Study 1Case Study 1
2. …Treatment
Combined Cyclical HRT (regular-bleed)
• Short-term
• Pregnancy?
Rees M, Purdie DW (2002), Management of the Menopause. Pg 112
57. Case Study 2Case Study 2
50 year old woman, posthysterectomy 3 years
(ovaries not removed), has menopausal
symptoms. She wants to know what are her
options for:
hot flushes
night sweats
Dryness of vagina
Dyspareunia
What would you advise her ?What would you advise her ?
58. Case Study 2Case Study 2
1.1.Health ScreenHealth Screen
• Baseline workup as is case 1
2. Treatment
• If normal mammogram and no contraindication, estrogen
only therapy can be started
• For fast relieve of vaginal symptoms, local application of
vaginal cream can be used for short term
59. Case Study 2Case Study 2
3. Weigh the benefits and risks
What are my risks ?
• Cardiovascular disease
− no protection
− If coronary artery disease present, higher risk of mortality in
the first year
• Breast Cancer
− Increased risk (MW study)
− No increase in risk (WHI Study)
− Increase mortality from breast cancer (MW Study)
60. Case Study 2Case Study 2
4. Alternative therapy if there are other risk
factors
What are my options?
• Prozac/Effexor
• Antihypertensives (Aldomet)
• Unproven therapy
− Black Cohosh
− Phytoestrogens
− Advise on spritual exercise yoga, taichi etc
61. Case Study 3Case Study 3
60 year old woman, has taken HRT
for 10 years is seeking your advice
whether she should stop or continue
taking HRT ?
What would you advise her ?What would you advise her ?
62. Counseling risk outweigh benefit
Health screening
Offer non pharmacological treatment
now consider HT rather than HRT?
65. ACOG: State-of-the-Art Guide to HormoneACOG: State-of-the-Art Guide to Hormone
TherapyTherapy
Combined hormone therapy should not be used for
prevention of diseases such as cardiovascular
disease, due to the small but significant increased
risk of conditions such as breast cancer, heart
attack, stroke, and blood clots;
Estrogen-alone therapy, used for women who
have had a hysterectomy, should also not be used
for prevention of diseases, due to increased risks
of blood clots and stroke.
Although ET carries fewer risks than combined HT,
women with a uterus should not use estrogen
alone due to their increased risk of uterine cancer;
66. ACOG: State-of-the-Art Guide toACOG: State-of-the-Art Guide to
Hormone TherapyHormone Therapy
Hormone therapies are appropriate for the relief
of vasomotor symptoms, so long as a woman has
weighed the risks and benefits with her doctor;
and
Women on combined HT or ET should take the
smallest effective dose for the shortest possible
time and annually review the decision to take
hormones.
67. NAMS (North American Menopause Society –NAMS (North American Menopause Society –
Sept 2003)Sept 2003)
The primary indication for systemic
hormone therapy is moderate and
severe menopausal symptoms: Hot
flashes, night sweats/insomnia,
mood swings
When treating moderate and severe
urogenital atrophy (vaginal dryness,
dyspareunia, urinary frequency, and
incontinence), local estrogen
preparations are preferred.
68. 2. HRT for treating menopausal symptoms
Treatment is justified since the benefits outweigh
the risks.
4. HRT for managing osteoporosis
Consider alternative therapies such as calcium,
biphosponates and the selective estrogen receptor
modulators. (SERMs)
69. 3. HRT for preventing cardiovascular diseases
3.1 Conventional HRT should not to be used for primary
prevention however a low dose HRT and transdermal
therapy can be considered to be used.
3.2 HRT should not be used for secondary prevention
against heart disease.
3.3 Women at risk of cardiovascular disease who wish to
discontinue HRT should consider dietary and lifestyle
changes (weight loss, regular exercise, stop smoking) as
well as the use of drugs to lower cholesterol and blood
pressure.
Editor's Notes
1 1 1
An increase in body weight and a shift in body fat distribution typically occur in the years following menopause. In one study,* over the course of a year, early postmenopausal women gained an average of 2.1 kg, even though caloric and macronutrient intake did not change. Accompanying this increased weight is a shift from gynoid to android fat distribution with a concomitant increased waist/hip ratio. This pattern of fat disposition is especially concerning given the association between abdominal obesity and cardiovascular disease risk. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fineberg SE, Waclawiw MA, James MK. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997;82:1549-1556. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, de Simone L, Orlandi R, Genazzani AR. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997;82:414-417. *Reubinoff BE, Wurtman J, Rojansky N, Adler D, Stein P, Schenker JG, Brzezinski A. Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study. Fertil Steril 1995;64:963-968 .
Hänggi W, Lippuner K, Jaeger MH, Birkhäuser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol 1998;48:691-699. OBJECTIVE: To compare the effects on body composition and body weight of tibolone vs two different sequential oral or transdermal oestrogen-progestogen hormone replacement therapies versus no therapy. PATIENTS AND METHODS: One hundred postmenopausal women were assigned to a control group (n = 26), or randomized to 1) tibolone (TIB) 2.5 mg/day (n = 28), 2) oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26), or 3) transdermal oestradiol patch (TTS) releasing 50 micrograms/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20). Body composition was measured at the base-line and every 6 months for 2 years by DXA (Hologic QDR 1000 W). RESULTS: Total body fat mass increased (P < 0.05) in controls (+3.6 +/- 1.5%) and in TTS treated (+4.7 +/- 2.2%), but not in PO (-1.2 +/- 2.4%) and TIB (-1.6 +/- 2.2%) treated subjects. This increase in total fat mass in controls and TTS treated women was mostly due to an increase in fat mass of the trunk (P < 0.05), but not legs. As a result, a redistribution of body fat to the trunk occurred in controls, TTS and TIB, but not in PO treated women (P < 0.05). Total lean body mass decreased (P < 0.02) in controls (-1.7 +/- 0.7%) and PO (-1.4 +/- 0.6%) but not in TTS (+0.3 +/- 0.8%) and TIB (+0.4 +/- 0.5%) treated subjects. CONCLUSIONS: The menopause is associated with an increase in total body fat and a decline in lean body mass. Oral oestradiol/dydrogesterone and tibolone prevent total body fat changes, whereas transdermal oestradiol/oral dydrogesterone and tibolone prevent the lean mass changes. Furthermore, oral oestradiol/dydrogesterone prevents the shift to a central, android fat distribution .
Highly effective in relieving vasomotor symptoms improvement usually seen within 4 weeks with
Amy JJ. Femoston®: effects on bone and quality-of-life. Eur Menop J 1995;2 (Suppl.):16-22. In a study in 186 postmenopausal women receiving femoston ® (2 mg 17ß-estradiol and 10 mg dydrogesterone) for one year, a clear reduction of menopausal symptoms such as hot flushes or night sweats was observed after 6 weeks and throughout the remaining observation period.
Stevenson JC, Teter P, Lees B . 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas 2001;38:197-203 Although the minimal dose of 17beta-estradiol in hormone replacement regimens was originally considered to be 2 mg/day, it is now increasingly accepted that a lower dose of 1 mg/day is effective in protecting women from the detrimental effects of the menopause. A 1-year, multicentre, double-blind, randomised study was conducted in 214 healthy postmenopausal women in order to assess the effect of 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) in preventing bone loss. Bone mineral density (BMD) was evaluable in 177 women who completed the study. In all women, a statistically significant increase from baseline in lumbar vertebrae (L2-L4) BMD was seen after 6 months ( + 2.4%; p < 0.01); this increase was somewhat greater after 12 months ( + 3.6%; p < 0.01). Similar effects were seen in the hip. After 6 months, BMD in the femoral neck, Ward's triangle and trochanter had increased by 0.20% (not significant [n.s.]), 0.32% (n.s.) and 1.08% (p < 0.01), respectively, compared with baseline. Greater increases were again seen after 12 months ( + 1.16%, + 1.62% and + 2.83%, respectively), all of which were statistically significant (p < 0.01) compared with baseline. The change in BMD from baseline did not differ significantly between the three dydrogesterone dosages for either L2-L4 or hip. All dosages were well-tolerated and amenorrhoea was achieved in over 70%. In conclusion, 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) results in a significant increase in lumbar vertebrae and hip BMD in postmenopausal women. The lower dose of oestrogen and the avoidance of cyclical bleeding make this a particularly suitable regimen for the prevention and treatment of osteoporosis in older women.